Form 4: Apyx Medical Director Receives 450,000 RSU Grant
Statement of Changes in Beneficial Ownership
Director Stavros G. Vizirgianakis was granted 450,000 restricted stock units in Apyx Medical Corporation.
Summary
- Director Stavros G. Vizirgianakis acquired 450,000 restricted stock units (RSUs) on June 11, 2026.
- The grant was issued at a price of $0 per unit.
- Following this transaction, the director's total beneficial ownership increased to 2,196,191 shares.
- The RSUs are subject to a multi-year vesting schedule based on continued service.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding director compensation, which is a routine corporate governance event.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
- Retention of key leadership through a structured three-year vesting schedule.
Negatives
- Potential for future shareholder dilution upon the eventual conversion of RSUs into common stock.
Risks
- Continued service requirement for vesting creates dependency on the director's ongoing tenure.
- Market volatility could impact the future value of the equity compensation.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on director equity compensation.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practices intended to align board incentives with long-term company performance in the medical device sector.
Comparison to Industry Standards
- The use of multi-year vesting schedules for director equity is consistent with standard corporate governance practices for publicly traded medical technology companies.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation | Grant of 450,000 restricted stock units to Director Stavros G. Vizirgianakis. | 06/11/2026 | Increases director's equity stake and aligns incentives with shareholders. |
Stakeholder Impact
- Shareholders: Potential minor dilution impact upon vesting.
- Director: Increased financial stake in the company's performance.
Next Steps
- Vesting of 150,000 units on June 11, 2026.
- Commencement of ratable vesting for remaining 300,000 units over the following two years.
Key Dates
| Date | Description |
|---|---|
| 06/11/2026 | Grant date of 450,000 restricted stock units and initial vesting of 150,000 units. |
| 06/11/2027 | Commencement of second tranche vesting (150,000 units over 12 months). |
| 06/11/2028 | Commencement of third tranche vesting (150,000 units over 12 months). |
Keywords
Apyx Medical, APYX, Form 4, Insider Trading, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.